Sovereign Investment Advisors LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 2,780 shares of the biopharmaceutical company’s stock, valued at approximately $257,000.
Several other hedge funds have also recently bought and sold shares of the company. Envestnet Portfolio Solutions Inc. increased its stake in Gilead Sciences by 6.5% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 111,772 shares of the biopharmaceutical company’s stock valued at $10,324,000 after purchasing an additional 6,815 shares in the last quarter. Choate Investment Advisors raised its holdings in shares of Gilead Sciences by 3.8% in the fourth quarter. Choate Investment Advisors now owns 9,722 shares of the biopharmaceutical company’s stock worth $898,000 after acquiring an additional 353 shares during the last quarter. Globeflex Capital L P raised its holdings in shares of Gilead Sciences by 90.2% in the fourth quarter. Globeflex Capital L P now owns 404,605 shares of the biopharmaceutical company’s stock worth $37,373,000 after acquiring an additional 191,901 shares during the last quarter. Natixis Advisors LLC raised its holdings in shares of Gilead Sciences by 97.6% in the fourth quarter. Natixis Advisors LLC now owns 334,737 shares of the biopharmaceutical company’s stock worth $30,920,000 after acquiring an additional 165,374 shares during the last quarter. Finally, Frank Rimerman Advisors LLC raised its holdings in shares of Gilead Sciences by 0.7% in the fourth quarter. Frank Rimerman Advisors LLC now owns 32,318 shares of the biopharmaceutical company’s stock worth $2,985,000 after acquiring an additional 232 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.
Gilead Sciences Trading Down 1.7 %
Shares of GILD opened at $111.44 on Friday. The stock’s 50-day moving average is $101.82 and its two-hundred day moving average is $92.82. The stock has a market cap of $138.78 billion, a PE ratio of 301.19, a P/E/G ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.
Gilead Sciences Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.84%. The ex-dividend date of this dividend is Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is currently 854.05%.
Insiders Place Their Bets
In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold a total of 311,285 shares of company stock worth $31,284,910 over the last quarter. 0.16% of the stock is owned by corporate insiders.
Analyst Ratings Changes
A number of equities analysts have recently weighed in on the company. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Wednesday, February 12th. BMO Capital Markets boosted their price target on Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Cantor Fitzgerald reissued a “neutral” rating and issued a $80.00 price target on shares of Gilead Sciences in a report on Wednesday, December 11th. Wells Fargo & Company lifted their price objective on Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. Finally, Daiwa America raised Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $104.52.
Get Our Latest Research Report on GILD
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
- Five stocks we like better than Gilead Sciences
- Where to Find Earnings Call Transcripts
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Where Do I Find 52-Week Highs and Lows?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What is a support level?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.